Reclaiming America’s Drug Innovation Edge

We are on a bureaucratic trajectory where American leadership in approving innovative medicines may not be sustainable and our most experienced pharmaceutical leaders are concerned. Former FDA commissioner Scott Gottlieb recently warned in The Washington Post that pressure from the East threatens to erode our leadership in drug development.

“As recently as five years ago, American drugmakers had all but shut the door on licensing new medicines from China. By…